Skip to content

Study · Case report or series · n = 1 · 2026

5 results

Case Report: Sustained pubertal suppression for 68 months with a single histrelin acetate implant in central precocious puberty.

Ilmer S, Salemi P

Frontiers in endocrinology9 Oct 2026

PMID42920604 (opens in a new tab)DOI10.3389/fendo.2026.1951374 (opens in a new tab)PepBankPUB-42920604
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The subcutaneous histrelin acetate implant is FDA-approved for 12 months of continuous gonadotropin-releasing hormone (GnRH) agonist therapy in central precocious puberty (CPP). Published data demonstrated sustained suppression with a single implant for up to approximately 24 months; however, efficacy beyond this duration has not been reported. A 7 years 5 month old female patient presented with bilateral Tanner 2 breast development, a bone age of 10 years, and laboratory findings consistent with early central activation. Treatment was delayed 11 months due to disruptions in care during the COVID-19 pandemic, and a histrelin implant was placed at age 8 years 5 months. The patient was lost to follow-up and returned at nearly 14 years of age, approximately 68 months after the implant placement, with primary amenorrhea and pubertal arrest. Laboratory evaluation before implant removal showed suppressed but detectable gonadotropins with a prepubertal estradiol, consistent with sustained partial suppression of the hypothalamic-pituitary-gonadal (HPG) axis sufficient to arrest pubertal progression. Her predicted adult height (PAH) of 167.6 cm (66 inches) approximated her mid-parental height (MPH) of 166.4 cm (65.5 inches). This case demonstrates that a single histrelin acetate implant may maintain clinically meaningful pubertal suppression for at least 68 months. These findings support broader investigations into the pharmacokinetics of extended implant use, given implications for reducing surgical burden and healthcare costs in CPP management.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a girl with central precocious puberty, primary amenorrhea persisted approximately 68 months after histrelin implant placement.

    In plain wordsIn a girl with early puberty, menstrual periods remained absent approximately 68 months after histrelin implant placement.

    Peptide
    Histrelin
    Outcome
    Direction not reportedPrimary amenorrhea
    Study

    n = 1

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated · subcutaneous implant · approximately 68 monthsAs given in this study (human).

    Source sentences

    Summary
    The patient was lost to follow-up and returned at nearly 14 years of age, approximately 68 months after the implant placement, with primary amenorrhea and pubertal arrest.
    2 context sentences
    Summary · context
    A 7 years 5 month old female patient presented with bilateral Tanner 2 breast development, a bone age of 10 years, and laboratory findings consistent with early central activation.
    Summary · context
    Treatment was delayed 11 months due to disruptions in care during the COVID-19 pandemic, and a histrelin implant was placed at age 8 years 5 months.
  2. 02HumanCase report or seriesEfficacy outcome

    In a girl with central precocious puberty, pubertal arrest persisted approximately 68 months after histrelin implant placement.

    In plain wordsIn a girl with early puberty, puberty remained arrested approximately 68 months after histrelin implant placement.

    Peptide
    Histrelin
    Outcome
    Direction not reportedPubertal arrest
    Study

    n = 1

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated · subcutaneous implant · approximately 68 monthsAs given in this study (human).

    Source sentences

    Summary
    The patient was lost to follow-up and returned at nearly 14 years of age, approximately 68 months after the implant placement, with primary amenorrhea and pubertal arrest.
    2 context sentences
    Summary · context
    A 7 years 5 month old female patient presented with bilateral Tanner 2 breast development, a bone age of 10 years, and laboratory findings consistent with early central activation.
    Summary · context
    Treatment was delayed 11 months due to disruptions in care during the COVID-19 pandemic, and a histrelin implant was placed at age 8 years 5 months.
  3. 03HumanCase report or seriesActivity measurement

    In a girl with central precocious puberty, gonadotropins remained suppressed but detectable before histrelin implant removal.

    In plain wordsIn a girl with early puberty, gonadotropins remained suppressed but detectable before histrelin implant removal.

    Peptide
    Histrelin
    Outcome
    DecreaseGonadotropin suppression
    Study

    n = 1

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated · subcutaneous implant · approximately 68 monthsAs given in this study (human).

    Source sentences

    Summary
    Laboratory evaluation before implant removal showed suppressed but detectable gonadotropins with a prepubertal estradiol, consistent with sustained partial suppression of the hypothalamic-pituitary-gonadal (HPG) axis sufficient to arrest pubertal progression.
    2 context sentences
    Summary · context
    A 7 years 5 month old female patient presented with bilateral Tanner 2 breast development, a bone age of 10 years, and laboratory findings consistent with early central activation.
    Summary · context
    Treatment was delayed 11 months due to disruptions in care during the COVID-19 pandemic, and a histrelin implant was placed at age 8 years 5 months.
  4. 04HumanCase report or seriesActivity measurement

    In a girl with central precocious puberty, estradiol remained prepubertal before histrelin implant removal.

    In plain wordsIn a girl with early puberty, estradiol remained at a prepubertal level before histrelin implant removal.

    Peptide
    Histrelin
    Outcome
    Direction not reportedPrepubertal estradiol
    Study

    n = 1

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated · subcutaneous implant · approximately 68 monthsAs given in this study (human).

    Source sentences

    Summary
    Laboratory evaluation before implant removal showed suppressed but detectable gonadotropins with a prepubertal estradiol, consistent with sustained partial suppression of the hypothalamic-pituitary-gonadal (HPG) axis sufficient to arrest pubertal progression.
    2 context sentences
    Summary · context
    A 7 years 5 month old female patient presented with bilateral Tanner 2 breast development, a bone age of 10 years, and laboratory findings consistent with early central activation.
    Summary · context
    Treatment was delayed 11 months due to disruptions in care during the COVID-19 pandemic, and a histrelin implant was placed at age 8 years 5 months.
  5. 05HumanCase report or seriesEfficacy outcome

    In a girl treated with histrelin, predicted adult height was 167.6 cm, approximating mid-parental height of 166.4 cm.

    In plain wordsIn a girl treated with histrelin, predicted adult height was 167.6 cm, near her mid-parental height of 166.4 cm.

    Peptide
    Histrelin
    Outcome
    Direction not reportedPredicted adult height
    Study

    n = 1

    Outcome group
    Linear growth · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneous implant · approximately 68 monthsAs given in this study (human).

    Measurements

    Predicted adult height
    167.6 cm
    reported height
    Predicted adult height
    66 inches
    reported height
    Mid-parental height
    166.4 cm
    reported height
    Mid-parental height
    65.5 inches
    reported height

    Source sentences

    Summary
    Her predicted adult height (PAH) of 167.6 cm (66 inches) approximated her mid-parental height (MPH) of 166.4 cm (65.5 inches).
    2 context sentences
    Summary · context
    A 7 years 5 month old female patient presented with bilateral Tanner 2 breast development, a bone age of 10 years, and laboratory findings consistent with early central activation.
    Summary · context
    Treatment was delayed 11 months due to disruptions in care during the COVID-19 pandemic, and a histrelin implant was placed at age 8 years 5 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.